ArticleFrontiers in nutrition2026
Clinical and prognostic value of dynapenia in patients with head and neck cancer: a multicenter cohort study. VALOR group.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck cancer (HNC), particularly in patients requiring intensive multimodal treatment, may substantially impair nutritional and functional status due to tumor burden and treatment-related toxicity. Dynapenia, defined as reduced muscle strength independent of muscle mass, has emerged as a critical prognostic marker in cancer, yet its role in HNC remains underexplored. This study aimed to assess the utility of handgrip strength (HGS) in identifying dynapenia and predicting clinical outcomes, in conjunction with advanced morphofunctional tools. Methods: In this prospective multicenter observational cohort study, 514 HNC patients undergoing active radiotherapy were evaluated. Muscle strength was assessed via HGS. Dynapenia was defined using two criteria: EWGSOP2 cut-offs and sex- and age-adjusted percentiles (P10) from Spanish normative data (dynapenia-PCO). Complementary assessments included bioelectrical impedance analysis (phase angle [PA], standardized phase angle [SPA], body cell mass [BCM], and fat-free mass index [FFMI]), nutritional ultrasound® (rectus femoris cross-sectional area [RF-CSA]), the Timed Up and Go test (TUG), and routine biochemical parameters. Logistic regression, ROC curves, Cox proportional hazards models, and machine learning techniques (random forest and decision trees) were used to identify predictors of dynapenia and overall survival. Results: Dynapenic patients presented significantly lower values of SPA, FFMI, BCM, and RF-CSA, as well as poorer performance (TUG) and nutritional biomarkers (e.g., albumin, total proteins). In multivariate logistic regression models adjusted for age, sex, and BMI, BIA (SPA: OR 0.80; Conclusion: In HNC patients, dynapenia defined by population-based percentiles provides a robust marker of impaired body composition and reduced survival. The integration of simple functional tools like dynamometry with advanced morphofunctional assessments offers a comprehensive and feasible strategy to identify high-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.